Wird geladen...
Remyelinating Pharmacotherapies in Multiple Sclerosis
We have witnessed major successes in the development of effective immunomodulatory therapies capable of reducing adaptive immune-mediated myelin damage in MS over the last 30 years. However, until it is possible to prevent MS or initiate treatment before it has already caused lesions there is a need...
Gespeichert in:
| Veröffentlicht in: | Neurotherapeutics |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer US
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5722779/ https://ncbi.nlm.nih.gov/pubmed/28948533 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-017-0577-0 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|